Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $314.58 million. The enterprise value is $253.34 million.
| Market Cap | 314.58M |
| Enterprise Value | 253.34M |
Important Dates
The next confirmed earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 82.57 million shares outstanding. The number of shares has increased by 159.75% in one year.
| Current Share Class | 82.57M |
| Shares Outstanding | 82.57M |
| Shares Change (YoY) | +159.75% |
| Shares Change (QoQ) | +7.83% |
| Owned by Insiders (%) | 7.12% |
| Owned by Institutions (%) | 45.66% |
| Float | 64.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.05 |
| Forward PS | 22.03 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.13
| Current Ratio | 7.13 |
| Quick Ratio | 6.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -32.97 |
Financial Efficiency
Return on equity (ROE) is -7,594.60% and return on invested capital (ROIC) is -298.51%.
| Return on Equity (ROE) | -7,594.60% |
| Return on Assets (ROA) | -46.79% |
| Return on Invested Capital (ROIC) | -298.51% |
| Return on Capital Employed (ROCE) | -88.10% |
| Weighted Average Cost of Capital (WACC) | 7.81% |
| Revenue Per Employee | $427,964 |
| Profits Per Employee | -$3.82M |
| Employee Count | 28 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +250.00% in the last 52 weeks. The beta is 0.58, so Opus Genetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +250.00% |
| 50-Day Moving Average | 3.83 |
| 200-Day Moving Average | 3.48 |
| Relative Strength Index (RSI) | 54.56 |
| Average Volume (20 Days) | 876,687 |
Short Selling Information
The latest short interest is 10.27 million, so 12.43% of the outstanding shares have been sold short.
| Short Interest | 10.27M |
| Short Previous Month | 8.23M |
| Short % of Shares Out | 12.43% |
| Short % of Float | 15.90% |
| Short Ratio (days to cover) | 8.67 |
Income Statement
In the last 12 months, Opus Genetics had revenue of $11.98 million and -$106.93 million in losses. Loss per share was -$1.42.
| Revenue | 11.98M |
| Gross Profit | -21.45M |
| Operating Income | -43.03M |
| Pretax Income | -106.93M |
| Net Income | -106.93M |
| EBITDA | -50.61M |
| EBIT | -50.61M |
| Loss Per Share | -$1.42 |
Balance Sheet
The company has $59.96 million in cash and $1.20 million in debt, with a net cash position of $58.76 million or $0.71 per share.
| Cash & Cash Equivalents | 59.96M |
| Total Debt | 1.20M |
| Net Cash | 58.76M |
| Net Cash Per Share | $0.71 |
| Equity (Book Value) | -21.10M |
| Book Value Per Share | -0.64 |
| Working Capital | 57.26M |
Cash Flow
| Operating Cash Flow | -38.99M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 53,000 |
| Net Borrowing | 1.00M |
| Free Cash Flow | -38.99M |
| FCF Per Share | -$0.47 |
Margins
| Gross Margin | -179.03% |
| Operating Margin | -359.13% |
| Pretax Margin | -892.36% |
| Profit Margin | n/a |
| EBITDA Margin | -513.47% |
| EBIT Margin | -513.47% |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -159.75% |
| Shareholder Yield | n/a |
| Earnings Yield | -34.26% |
| FCF Yield | -12.49% |
Analyst Forecast
The average price target for Opus Genetics is $10.61, which is 178.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.61 |
| Price Target Difference | 178.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | 45.05% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of -5.39 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.39 |
| Piotroski F-Score | 2 |